Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Description
NX 1607 (Cbl-b-IN-3) is an inhibitor of CBL-B (Casitas B-lineage lymphoma proto-oncogene B), a RING-type E3 ubiquitin ligase. NX 1607 acts as an intramolecular glue. In vitro, NX 1607 activates MAPK/ERK signaling pathway and enhances T-cell activation in primary T cells and Jurkat T cells. In vivo, NX 1607 decreases tumor growth in cell lymphoma models. NX 1607 is orally bioavailable.
Specifications
Specifications
| Chemical Name or Material | 2,3-Dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-1H-isoindol-1-one |
| CAS | 2573775-59-2 |
| Quantity | 50 mg |
| Target | Molecular Glues |
| Molecular Formula | C30H34F3N5O |
| Purity | 98% |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?
